Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Considerations for ART Optimization in Patients With Multimorbidity/Polypharmacy (23 minutes)
  • CME
  • CE

Learn about the risk of drug-drug interactions and ART management strategies to reduce drug-drug interactions and adverse events in persons with comorbidities
Kristine Erlandson, MD
Rajesh T. Gandhi, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: April 24, 2020 Expiration: April 23, 2021

This program is divided into short segments which you can review from the Activity landing page.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Incorporate the latest data on HIV regimen safety and tolerability into patient discussions of first-line ART options
  • Apply appropriate ART modification strategies for patients experiencing adverse events or who are at risk of other conditions for which ART safety may be a concern
  • Apply appropriate ART and non-ART medication management strategies for patients with multimorbidity and/or polypharmacy to avoid contraindications and minimize adverse events

Information on this Educational Activity

Faculty

Kristine Erlandson, MD

Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Kristine M. Erlandson, MD, has disclosed that she has received funds for research support from Gilead Sciences and has served on advisory boards or panels with Gilead Sciences and ViiV Healthcare.
Rajesh T. Gandhi, MD

Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has no relevant conflicts of interest to report.

Staff

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Associate Scientific Director

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Carwright, PhD, has no relevant conflicts of interest to report.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers who care for patients with HIV infection.

Goal

The goal of this activity is to improve learners’ competence in applying the latest safety and tolerability data when individualizing ART regimen selection and management for patients with HIV infection.

USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Continuing Medical Education

Credit Designation

USF Health designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.25 contact hours may be earned by learners who successfully complete this continuing nursing education activity.

Pharmacist Continuing Education

USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1.25 contact hours (0.0125 CEU). Universal program number is as follows: 0230-9999-20-014-H02-P

Type of activity: Knowledge

For Pharmacists:
It is the responsibility of the pharmacy participant to ensure the provider has the learner’s birthday and e-Profile ID (ePID)/NABP number; it is the responsibility of the provider to submit to CPE Monitor participant information within 60 days of the activity for all participants who have attended, attested to their participation, and provided their ePID/NABP number and birthdate. 

ACPE indicates it is the responsibility of the pharmacy professional to confirm the status of their NABP contact hours before 60 days past the activity. If there are any discrepancies, contact the provider immediately. You may contact USF Health through cpdsupport@usf.edu.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 24, 2020, through April 23, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

April 2020 data from Tsepamo study on NTD prevalence following dolutegravir and other ART exposure at conception from AIDS 2020 reported by CCO

Released: July 11, 2020

Latest data from a pooled analysis of 4 trials of switching to BIC/FTC//TAF in patients aged 65 years or older from AIDS 2020 reported by CCO

Released: July 11, 2020

Data from AIDS 2020: Virtual on Week 48 metabolic changes (lipids, insulin resistance) after switch from TAF-based ART to DTG/3TC in TANGO, reported by CCO

Released: July 11, 2020

AIDS 2020: Virtual data on weight change with switch to DOR/3TC/TDF among virologically suppressed adults in phase III DRIVE-SHIFT as reported by CCO

Released: July 10, 2020
Provided by USF Health

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?